X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Gavel with drugs The ruling “clears the way for us to begin obtaining discovery from the manufacturers and PBMs so we can shine the light on exactly what has driven insulin prices sky-high,’’ Steve Berman, a plaintiffs’ lawyer. (Photo: Shutterstock)

Novo Nordisk A/S and two other insulin makers must face claims they gouged diabetes patients through deceptive price lists for their life-saving drugs.

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.